On 8 July 2026, the European Commission published a draft delegated directive updating the time-limited lead and cadmium exemptions in Annexes III and IV of the RoHS Directive (2011/65/EU). Public feedback closes on 5 August 2026. For manufacturers placing electrical and electronic equipment on the EU market, this is the moment to map exposure, because several base exemptions are being narrowed rather than simply renewed. Understanding the EU RoHS lead and cadmium exemptions now protects both market access and technical file integrity later.

If your team is unsure which parts rely on these exemptions, a structured review is the fastest way to find out. You can request a compliance review to scope your Annex III and IV exposure before the feedback window closes.

Key Takeaways

📌 The draft delegated directive updates roughly 32 sub-entries across RoHS Annex III and Annex IV, covering lead and cadmium in lamps, optical glass, solders, lasers, sensors, and imaging systems.

⏳ The public feedback period runs from 8 July to 5 August 2026 through the Commission's "Have your say" portal, initiative 14509.

⚠️ Several base exemptions are being narrowed into specific sub-entries, so a product justified under old wording may not automatically fall under a new sub-entry.

📊 Proposed validity periods range from 12 to 78 months after entry into force, expressed as "EIF + N months" because no adoption date exists yet.

🏭 Medical devices (Category 8) and industrial monitoring and control instruments (Category 9) face the shortest transition periods and the most restructuring.

📄 Once adopted, Declarations of Conformity and technical files citing broad legacy entries will need re-mapping to the exact sub-entry that matches each application.

🤖 BOM-level compliance intelligence and automated supplier data collection reduce the manual burden of re-screening thousands of parts against revised exemption numbers.

Executive Regulatory Overview

The RoHS Directive restricts ten hazardous substances in electrical and electronic equipment, including lead and cadmium. Annexes III and IV list the specific applications that are temporarily exempt from those restrictions. The 8 July 2026 draft is an omnibus instrument that consolidates the outcomes of several stakeholder evaluation packs conducted between 2020 and 2024 into a single delegated act now moving toward adoption.

For compliance leaders, the practical significance is not that exemptions exist. It is that many are being restructured, re-scoped, and given new expiry clocks. Treating this as routine housekeeping is the main risk. Reviewing the EU RoHS framework against your current product portfolio is the first defensive step.

Framework and Legal Scope

The draft amends Directive 2011/65/EU under the Article 290 TFEU delegated-act procedure. Annex III covers general exemptions across categories. Annex IV covers exemptions specific to Category 8 medical devices and Category 9 monitoring and control instruments. Article 5 allows the Commission to grant, renew, narrow, or revoke exemptions based on the availability of substitutes, socioeconomic impact, and effects on innovation.

Nothing in the draft is legally binding today. The current Annex III and Annex IV text, including existing expiry dates, remains in force until a directive is adopted and published in the Official Journal. Manufacturers can review the authoritative text through the European Commission RoHS Directive page and the consolidated Directive 2011/65/EU on EUR-Lex.

What Is Changing in Annex III

Annex III changes touch lighting, optical and crystal glass, solders, and passive components. The most important pattern is scope narrowing, where a broad base point is split into precise sub-entries with different validity clocks. Manufacturers relying on generic wording should confirm which specific sub-entry now applies to each part, a task that maps directly to BOM-level compliance tracking.

Representative Annex III Proposals

Because these are draft figures, all validity periods are expressed relative to entry into force. That is why continuous regulatory intelligence and horizon scanning matters, since fixed calendar dates only appear after Official Journal publication.

What Is Changing in Annex IV

Annex IV carries the most consequential restructuring, and it affects the two categories least able to substitute quickly. Oxygen sensors, gas and He-Cd lasers, X-ray and imaging assemblies, and MRI, NMR, and SQUID superconductor applications are all re-scoped into detailed sub-entries.

Representative Annex IV Proposals

Two nuances deserve attention. First, per the draft text, entries 1(b)-I and 1(b)-II are tied to devices and consumables placed on the market before the EU medical device regulatory cut-over, so confirm which of your products fall on each side of that line. Second, general He-Cd laser use gets 12 months, while Raman spectrometer use for semiconductor stress measurement gets 30. Manufacturers in this space should coordinate early with medical devices and semiconductor and high-tech compliance owners.

Struggling to trace which parts carry these substances? You can speak with a compliance specialist to structure a substance-level review across your bill of materials.

Industries and Product Categories Affected

The draft reaches a broad set of manufacturers, but the impact is concentrated in precision and regulated hardware.

🏭 Lighting: fluorescent, discharge, sun-tanning, and phototherapy lamps.

🏭 Optical components and crystal glass: filter glass, reflectance standards, precision optics.

🏭 Laser systems: gas lasers, HeNe interferometry, He-Cd Raman spectroscopy.

🏭 Passive electronic components: ceramic multilayer capacitors, cermet trimmer potentiometers.

🏭 Medical devices: phototherapy, oxygen sensor consumables, MRI and NMR systems.

🏭 Industrial monitoring and control: gas analysis, IR spectroscopy, Hersch cell sensors, SQUID detectors.

🏭 X-ray and imaging: X-ray tubes and image intensifiers.

Electronics producers with mixed portfolios should align this review with existing electronics manufacturing compliance programs so that a single substance change can be traced across every affected product.

Industries affected by EU RoHS lead and cadmium exemptions in the 2026 draft directive.

Click on image to view full

Documentation and Technical File Impact

The operational sting arrives after adoption, not before. Once the directive is published, Declarations of Conformity and technical files that cite broad legacy points, such as 5(b), 13(a), 13(b), 18(b), 24, 29, 32 and 34 in Annex III, or 1(b), 4, 9, 11 and 12 in Annex IV, will need re-mapping to the specific sub-entry that matches each real application. Where a base point is narrowed, a generic justification may no longer hold.

This is a data versioning problem as much as a regulatory one. Teams need a centralized environmental compliance record that stores which exemption a product relied on, when, and with what supporting evidence, so historic states remain retrievable during any future review.

Audit Types and Evidence Integrity

Exemption changes surface across four distinct audit contexts, and each expects different evidence:

1. Internal audits: confirm that technical files cite the correct current sub-entry.

2. Customer audits (OEM-driven): OEMs increasingly demand proof that suppliers tracked the change and updated declarations on time.

3. Regulatory inspections: national market surveillance authorities and ECHA-linked processes may request point-in-time evidence.

4. Certification audits: ISO 9001, IATF 16949, and ISO 14001 assessors look for controlled documentation and change management.

Audit readiness here means evidence chain integrity: who submitted a declaration, when it was submitted, and under what authority. Immutable audit logs and time-stamped declarations turn a scramble into a query. No software makes a company "audit-proof," and no tool eliminates findings. The realistic objective is audit-ready posture that reduces surprises and shortens response time. The stay audit-ready across frameworks approach is built around exactly this point-in-time retrieval need, similar to the customer trust center models used by companies like Apple, Microsoft, and major automotive OEMs.

Compliance Risk and Enforcement Exposure

The dominant risk is not a fine on day one. It is losing market access when an exemption a product depends on expires and the technical file was never updated. Because validity periods run from an unknown entry-into-force date, teams that wait for calendar certainty may have very little time to act once the clock starts, particularly on the 12-month Annex IV entries.

Secondary exposure includes customer disqualification when OEM audits find stale declarations, and supply chain disruption when upstream suppliers cannot confirm which exemption their component relies on. Pairing this review with REACH SVHC obligations avoids duplicated effort, since the same parts and suppliers often appear in both programs.

Timeline and Adoption Outlook

Because this is an omnibus consolidation of multi-year assessments, adoption could proceed relatively quickly once feedback closes. Based on comparable recent RoHS delegated directives, a transposition window of roughly seven months from Official Journal publication is a reasonable planning assumption, though the exact figure only becomes certain at publication. This is a separate workstream from the Pack 29 consultation, which addresses mercury and certain Annex IV revocation requests and should be tracked independently.

Compliance Preparation Checklist

✅ Screen customer BOMs and technical files against the specific sub-entry numbers, not the general legacy points.
✅ Prioritize Category 8 medical and Category 9 industrial products, which carry the shortest provisional validity and the deepest restructuring.
✅ Confirm the medical device placed-on-market cut-off referenced in Annex IV 1(b)-I and 1(b)-II against the draft Annex text.
✅ Do not conflate this draft with Pack 29; track them separately and submit separate feedback if needed.
✅ Decide by early August whether to submit feedback via initiative 14509, especially where a validity period looks too short for a realistic substitution timeline.
✅ Prepare to update Declarations of Conformity and technical files with the new sub-entry numbers once adopted.
✅ Centralize evidence so historic exemption states remain retrievable for future audits.

A structured way to test your position is the Customer Audit Readiness Scorecard, a short self-assessment covering documentation completeness across RoHS, REACH, Prop 65, PFAS, and conflict minerals, plus historic-state retrievability and hours-to-audit-pack response time.

How AI and Automation Reduce the Burden

Re-mapping thousands of parts against ~32 revised sub-entries is not a task that manual spreadsheets handle well. This is where AI-native compliance automation changes the economics of the work.

Certivo acts as a compliance data backbone that links each part, supplier, and Declaration of Conformity to the exact exemption it relies on. When an exemption is narrowed, the system flags every affected product rather than leaving engineers to search by hand. BOM-level material mapping connects substance data to specific products, so impact analysis is a query, not a project.

CORA-powered regulatory intelligence monitors changes to RoHS Annexes III and IV and related frameworks, alerting teams before clocks start rather than after. Combined with automated supplier data collection and AI document parsing that validates certificates at intake, this shifts an organization from reactive scrambles toward continuous, audit-ready readiness. Teams managing overlapping chemical rules can extend the same backbone to chemical and hazmat compliance without rebuilding their data model.

AI-powered RoHS exemption change management workflow linking Annex updates to audit-ready compliance evidence.

Click on image to view full

Executive Conclusion

The 2026 draft delegated directive on EU RoHS lead and cadmium exemptions is not yet law, but it sets the direction clearly. Base exemptions are being narrowed into precise sub-entries with validity clocks as short as 12 months, and the heaviest impact falls on medical and industrial instrument makers with limited substitution options. The manufacturers who fare best will be those who map their exposure now, decide whether to submit feedback before 5 August 2026, and hold the evidence needed to update technical files the moment the directive is adopted.

Certivo gives compliance, engineering, and procurement teams one connected record of every substance, supplier, and declaration, so a single regulatory change becomes a traceable, auditable event rather than a fire drill. To understand your specific exposure across Annexes III and IV, book a compliance risk assessment.